CDRH Leadership Changes May Be Imminent; NCI’s Ellen Feigal To Leave Institute
This article was originally published in The Gray Sheet
Executive Summary
FDA is vetting a list of more than 20 candidates for a CDRH clinical deputy spot - a position that may grow in stature with the potential departure of Director David Feigal
You may also be interested in...
Schultz to head CDRH for rest of 2004?
Device center medical deputy post unlikely to be filled until CDRH obtains a permanent director, according to FDA staff. The agency had previously suggested that a medical deputy appointment was imminent, and that more than 20 candidates were under review (1"The Gray Sheet" April 19, 2004, p. 3). With the April 30 departure of former CDRH director David Feigal, however, staffers say Dan Schultz could remain acting director through the November elections...
Schultz to head CDRH for rest of 2004?
Device center medical deputy post unlikely to be filled until CDRH obtains a permanent director, according to FDA staff. The agency had previously suggested that a medical deputy appointment was imminent, and that more than 20 candidates were under review (1"The Gray Sheet" April 19, 2004, p. 3). With the April 30 departure of former CDRH director David Feigal, however, staffers say Dan Schultz could remain acting director through the November elections...
Feigal Aids Small To Mid-Sized Device, Biologic Firms In Consultant Capacity
Former CDRH Director David Feigal, MD, will commit at least three days a week to NDA Partners, a product development consulting firm, where he will help build a client base for medical devices and biologics